Skip to main content
TISSUE REGENIX GROUP PLC logo

TISSUE REGENIX GROUP PLC — Investor Relations & Filings

Ticker · TRX ISIN · GB00BNTXR104 LEI · 213800PNOD5UHQUFJI36 IL Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2024-06-14 Capital/Financing Update
Country GB United Kingdom
Listing IL TRX

About TISSUE REGENIX GROUP PLC

https://www.tissueregenix.com/

Tissue Regenix Group PLC is a medical technology company specializing in regenerative medicine. The company develops and commercializes biological products designed to repair and regenerate human tissue. It employs proprietary decellularization platform technologies to process human and animal tissues, creating acellular scaffolds. When implanted, these scaffolds support the patient's own cells in repopulating and regenerating the damaged area. The company's portfolio serves three main clinical areas: biosurgery for complex wound care, orthopaedics for sports medicine and bone graft substitutes, and dental applications for tissue and bone repair. Key products include DermaPure®, OrthoPure® XT, and the Matrix® line of bone graft substitutes.

Recent filings

Filing Released Lang Actions
Building purchase
Capital/Financing Update Classification · 1% confidence The document is identified by the header 'RNS Number : 3358S' and concludes with standard boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and the FCA. The content announces a specific corporate action: the purchase of a leased building as part of an expansion plan. This is a material, non-financial announcement made via the Regulatory News Service (RNS). Since it is a specific corporate event announcement distributed through the RNS system and does not fit into more specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2024-06-14 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states it is the 'Result of Annual General Meeting' and provides a detailed table showing the results of proxy votes for resolutions (Resolution 1 through 12) passed at the AGM held on April 25, 2024. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core content is the voting result tabulation, not the AGM presentation materials (AGM-R) or the proxy solicitation document itself (PSI).
2024-04-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the 'RNS Number' header and contains the standard formatting for a regulatory notification disseminated via RNS (Regulatory News Service). Specifically, the form title is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which corresponds to the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2024-04-05 English
Final results for the year ended 31 December 2023
Earnings Release Classification · 1% confidence The document is an 'Earnings Release' (ER) issued by Tissue Regenix Group PLC. It contains key financial highlights (revenue growth, adjusted EBITDA, gross profit) and operational highlights for the fiscal year ended 31 December 2023. While it mentions the upcoming publication of the full Annual Report and AGM notice, the document itself provides the substantive financial results and management commentary, fitting the definition of an Earnings Release. FY 2023
2024-03-19 English
Notice of Results
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3670 characters) released via RNS (Regulatory News Service) from the London Stock Exchange. The title is 'Notice of full year results Investor presentation'. The text explicitly states that the company 'will announce its final results for the year ended 31 December 2023 on Tuesday 19 March 2024' and mentions hosting an investor briefing. This structure—announcing the future publication date and details of an associated presentation/briefing—fits the definition of a Report Publication Announcement (RPA). It is not the full results document itself (which would likely be 10-K or IR), nor is it the presentation (IP) or the results release (ER), but rather the notice *about* the upcoming release and presentation.
2024-03-01 English
First EU shipment & new distributor agreements
Regulatory Filings Classification · 1% confidence The document starts with 'RNS Number' and is dated '06 February 2024'. It announces operational updates (first shipment, new distributor agreements) and includes commentary from the CEO. The footer explicitly states, 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This structure strongly indicates a general regulatory announcement distributed via the RNS system that does not fit into a more specific category like ER, DIV, or DIRS. Given the nature of the announcement (business operations update) and the distribution channel (RNS), the most appropriate classification is the general Regulatory Filings category (RNS), as it is not a formal report (like 10-K or IR) but a market update.
2024-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.